dear
sir
today
report
global
number
confirm
case
surpass
number
known
case
increas
sever
thousand
everi
day
march
publicli
character
pandem
issu
seriou
concern
deserv
moment
attent
coronavirus
famili
virus
caus
respiratori
ill
caus
ill
anim
seven
known
type
coronavirus
caus
ill
human
coronaviru
sever
acut
respiratori
one
virus
caus
ill
current
known
coronaviru
though
still
learn
exactli
put
someon
greater
risk
develop
sever
ill
earli
inform
indic
older
patient
chronic
medic
condit
hypertens
diabet
cardiocerebrovascular
diseas
may
higher
risk
infect
caus
like
disturb
metabol
regul
diabet
patient
may
face
alter
immun
respons
background
alreadi
compromis
health
statu
owe
diabetesrel
complic
andor
age
import
find
patient
hyperglycemia
viral
infect
signific
worsen
symptom
impli
greater
morbid
patient
compar
without
diabet
howev
pathophysiolog
associ
remain
uncertain
known
whether
hyperglycemia
chang
virul
infect
viru
modifi
glycem
metabol
know
diabet
patient
suscept
infect
impact
glucos
metabol
dm
disord
glucos
metabol
chronic
inflammatori
condit
character
multipl
chang
lipid
carbohydr
protein
profil
inflammatori
process
due
hyperglycemia
lead
increas
synthesi
glycosyl
end
product
age
activ
macrophag
cell
immun
system
increas
oxid
stress
promot
synthesi
proinflammatori
cytokin
besid
stimul
synthesi
adhes
molecul
facilit
inflamm
tissu
inflammatori
process
complic
might
provid
higher
propens
infect
greater
sever
condit
anoth
import
issu
inflammatori
immun
respons
occur
diabet
patient
acquir
viral
infect
well
whether
viru
interfer
insulin
secret
glycem
control
stage
biolog
mechan
relationship
diabet
known
associ
sever
case
death
pronounc
need
develop
hypothesi
explain
causal
path
underli
sever
clinic
present
infect
subsequ
death
diabet
patient
biochem
test
also
essenti
clarifi
molecular
pathophysiolog
involv
associ
dm
substanti
public
health
import
deserv
proper
attent
sinc
larg
divers
popul
affect
global
nowaday
comorbid
pose
relev
threat
human
health
prospect
welldesign
studi
elucid
biolog
mechan
best
clinic
manag
associ
urgent
need
use
see
review
publish
journal
diabet
covid
infect
highlight
peopl
diabet
death
rate
perhap
around
four
time
background
popul
note
suggest
death
chinawuhan
peopl
diabet
clearli
import
understand
confound
form
associ
risk
factor
die
infect
notabl
age
cardiovascular
diseas
explain
excess
need
understand
better
mitig
risk
report
death
occur
context
pneumon
particularli
onset
adult
respiratori
distress
syndrom
ard
condit
excess
fluid
alveoli
block
ga
exchang
air
blood
peopl
diabet
mani
cardiovascular
diseas
cvd
without
diabet
permeabl
vasculatur
identifi
sinc
albumin
lead
kidney
microand
macroalbuminuria
even
prior
late
blush
retina
intraven
fluoresc
marker
inject
leaki
vasculatur
associ
vascular
inflamm
metabol
syndrom
steatohepat
well
cvd
per
se
would
seem
far
stretch
absenc
research
yet
assum
prior
enhanc
vascular
permeabl
could
account
increas
rate
ard
death
peopl
diabet
particularli
type
diabet
also
cvd
asid
research
would
suggest
alreadi
albuminuria
routin
yearli
test
peopl
diabet
higher
liver
enzym
marker
alt
perhap
diabet
associ
dyslipidaemia
low
hdl
cholesterol
take
particular
step
selfisol
unclear
fast
vascular
inflamm
amelior
improv
blood
glucos
control
nearli
glucoselow
medic
reduc
microalbuminuria
time
tight
glucos
control
infect
person
insulin
would
meanwhil
seem
sensibl
poor
glucos
control
known
interfer
leukocytelymphocyt
function
dear
editor
recent
publish
articl
highlight
special
concern
manag
patient
diabet
time
pandem
concern
use
angiotensin
convert
enzym
ace
inhibitor
angiotensin
receptor
blocker
arb
clarifi
public
ii
summaris
current
evid
regard
tri
arriv
reason
conclus
absenc
vaccin
antivir
drug
infect
sever
therapeut
approach
studi
one
approach
use
inhibitor
renin
angiotensin
system
name
ace
inhibitor
arb
hand
concern
rais
fact
patient
agent
might
increas
risk
infect
sever
acut
respiratori
syndrom
sar
angiotensin
convert
receptor
sar
well
coronavirus
express
type
alveolar
epitheli
cell
endothelium
sglycoprotein
surfac
coronaviru
bind
lead
conform
chang
sglycoprotein
allow
proteolyt
digest
host
cell
proteas
ultim
lead
intern
virion
iii
viral
sglycoprotein
inhibit
potenti
target
therapi
possibl
vaccin
develop
essenti
coronaviru
infect
blockad
thought
benefici
preventingtr
infect
retrospect
analysi
found
reduc
rate
death
endotrach
intub
patient
viral
pneumonia
continu
ace
inhibitor
iv
mice
coronaviru
induc
lung
injuri
show
improv
treat
losartan
v
far
infect
concern
data
ra
activ
effect
blockad
limit
present
hypokalaemia
could
marker
ra
activ
high
incid
hypokalaemia
report
patient
infect
vi
despit
small
studi
suggest
benefit
drug
act
ra
data
albeit
scarc
anim
model
human
studi
treatment
ace
inhibitor
arb
could
caus
regul
vii
ibuprofen
thiazolidinedion
also
shown
viii
ix
increas
express
could
theoret
increas
risk
infect
sar
could
concern
peopl
diabet
alreadi
elev
risk
infect
mani
factor
howev
current
evid
support
hypothesi
view
lack
robust
evid
either
benefit
harm
reason
patient
continu
use
ace
inhibitor
arb
recommend
european
societi
cardiolog
council
hypertens
european
societi
hypertens
x
xi
forti
cdoc
hospit
chirag
enclav
